The U.S. Onychomycosis Market 2018 - Profiles for Valeant Pharmaceuticals, Pfizer, Novartis and Johnson & Johnson - ResearchAndMarkets.com
The U.S. onychomycosis market (prescription drugs) has increased with a healthy growth rate over the years and is expected to increase further during the forecasted period.
The U.S. onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.
Key Topics Covered1. Executive Summary
3. Global Market Analysis
4. U.S. Market Analysis
5. Competitive Landscape
6. Company ProfilesValeant PharmaceuticalsPfizer Inc.Novartis AGJohnson & Johnson
For more information about this report visit https://www.researchandmarkets.com/research/hcgc2m/the_u_s?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181001005419/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Infectious Diseases Drugs
KEYWORD: UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 10/01/2018 06:18 AM/DISC: 10/01/2018 06:19 AM